1 12, 2015

Orbsen Awarded 6 Million Euros to Test Cell Therapy for Diabetic Kidney Disease

2018-03-15T12:35:48+00:00December 1st, 2015|

8 June 2015: TheJournal.ie: “NUI Galway spin-out company Orbsen Therapeutics used patented technology to discover the stromal cell therapy, which uses cells purified from healthy donor bone marrow. The four-year research project will see some 48 patients taking part in clinical trials in Galway, Belfast, Birmingham and Bergamo to test the treatment.” […]

1 12, 2015

NUI Galway Leads Stem Cell Research on Diabetic Kidney Disease

2015-12-13T07:06:37+00:00December 1st, 2015|

 8 June, 2015:  The Irish Times covered the kick-off of Nephstrom. "The new €6 million EU-funded project, led by NUIG Regenerative Medicine Institute director Prof Timothy O’Brien, will evaluate a type of “next-generation” cell therapy discovered by researchers at the NUIG campus company Orbsen Therapeutics." Read the complete story at the Irish Times, or learn [...]

18 11, 2015

ORBCEL-M and Nephstrom In the Spotlight

2015-12-01T10:45:28+00:00November 18th, 2015|

The Nephstrom project and the promise of Orbsen’s stromal cell therapy are up for discussion when RegMedNet interviews Remedi Chair (and Orbsen Director), Professor Timothy O’Brien. “Funded by a €6-million grant from the European Union Horizon 2020 programme and including many partners, the project is now setting up a stem cell factory with the NHS [...]

18 11, 2015

A Day in the Life of Orbsen’s Dr Steve Elliman

2018-03-15T12:35:48+00:00November 18th, 2015|

Smartfutures interviews Dr. Steve Elliman, head of research at Orbsen Therapeutics, who says no two days are the same at his Galway start-up. Describe your typical day My chief function is to manage 11 research scientists in the lab. Another role is grant writing. We’re a start-up so we don’t [...]

17 11, 2015

Orbsen Cell Therapy Selected for Diabetic Wound Clinical Trial

2018-03-15T12:35:48+00:00November 17th, 2015|

Pictured L to R: Professor Tim O’Brien, Brian Molloy and Dr Stephen Elliman of Orbsen Therapeutics. Monday, 12 May 2014 Orbsen Therapeutics’ proprietary stromal cell therapy (Cyndacel-M™) has been selected to be tested in a EU Framework 7 (FP7) funded safety trial for the treatment of non-healing, ulcerating wounds in [...]

17 11, 2015

Orbsen Project Receives Industrial Research Fellowship

2015-12-13T15:38:35+00:00November 17th, 2015|

12 June, 2014: The Minister for Jobs, Enterprise and Innovation, Richard Bruton TD, this week announced the award of funding of over €1.7 million to support twenty new industry-academia partnerships through the Science Foundation Ireland Industry Fellowship Programme, including Dr Daniel O’Toole’s work on the development of a regulatory compliant cell product for Acute [...]